Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Summit Corporation (SUMM)

  Print      Mail a friend

Tuesday 19 July, 2011

Summit Corporation


RNS Number : 6129K
Summit Corporation PLC
18 July 2011

Summit Corporation plc

("Summit" or "the Company")





Oxford, UK, 19 July 2011, Summit Corporation plc (AIM: SUMM), a UK drug discovery company, is pleased to announce that it is presenting the recently reported positive results from its programme targeting Alzheimer's disease, and other neurological disorders, at the Alzheimer's Association International Conference on Alzheimer's Disease 2011 ('ICAD 2011') which is currently being held in Paris. 


Alzheimer's disease is a progressive and debilitating neurodegenerative disorder and is the most common form of dementia.  It remains an area of high unmet medical need with current treatment options only providing symptomatic relief. 


The title of the presentation is 'Reduction of Tau phosphorylation mediated by novel OGA inhibitors' and it highlights:

·    Summit's focus on a new and potentially disease modifying strategy for the treatment of Alzheimer's disease that targets the enzyme OGA (O-linked N-acetylglucosaminidase)

·    The identification and subsequent optimisation to generate extremely potent, selective and non-cytotoxic inhibitors of OGA using Summit's innovative Seglin™ technology drug discovery platform

·    Demonstration in a human cellular model that the Seglin OGA inhibitors reduce levels of an abnormal form of the protein Tau, found in the brain of Alzheimer's patients and which causes the formation of toxic 'tangles' and ultimately results in disease symptoms.


Interest in Tau protein as an approach for developing drugs to treat Alzheimer's disease continues to increase as evidenced by the growing number of peer-reviewed scientific publications.†  Tau protein plays a role in maintaining the healthy function of nerve cells in the brain but the formation of abnormal hyperphosphorylated Tau protein destabilises cells and results in formation of Tau protein aggregates ('tangles').  As results from Summit's early-stage programme show, inhibition of OGA by Seglins can reduce the levels of hyperphosphorylated Tau and potentially offers a new strategy for treating this disease.


A copy of the poster is available on request from


Dr Richard Storer, Chief Scientific Officer of Summit commented, "We are pleased to share these positive results at the 2011 ICAD meeting.  The identification of highly potent yet selective Seglins that inhibit OGA is a very important step forward as this enzyme target represents a new potential disease modifying approach for the treatment of Alzheimer's disease."


†          1. Targeting Tau Protein in Alzheimer's Disease, Cheng-Xin Gong, Inge Grundke-Iqbal and Khalid Iqbal, Drugs Aging 2010; 27 (5): 351-365.

            2. Advances in Tau-focused Drug Discovery for Alzheimer's Disease and Related Tauopathies, Kurt R. Brunden, John Q. Trojanowski, and Virginia M.-Y. Lee, Nature Reviews Drug Discovery, 2009 October; 8(10): 783-793.


- END -


For more information, please contact:



Barry Price, PhD

Richard Pye, PhD

Tel: +44 (0)1235 443939

Singer Capital Markets (Nominated Adviser)

Shaun Dobson / Claes Spång

Tel: +44 (0)20 3205 7500

Peckwater PR

Tarquin  Edwards

Tel: +44 (0)7879 458 364



Notes to Editors


About Summit

Summit is an Oxford, UK based drug discovery company with an innovative technology platform called Seglins for the discovery of new medicines, a portfolio of drug programme assets and a commercial strategy of signing multiple early-stage deals.


Seglin technology is using new chemistry to access biological drug targets that cannot be exploited by conventional drug discovery approaches.  Summit's internal research is currently focussed in the high-value therapy areas and the Company will further exploit the technology's wider potential through strategic alliances.  Summit's programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection.


Summit's commercial strategy focuses on signing multiple early-stage drug programme and technology platform deals that generate upfront cash, remove development costs from the Company, and retain valuable upside potential.


Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM.  Further information is available at





This information is provided by RNS
The company news service from the London Stock Exchange